Stifel Financial Corp grew its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 103.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 440,666 shares of the company's stock after buying an additional 224,594 shares during the period. Stifel Financial Corp's holdings in Takeda Pharmaceutical were worth $6,266,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors also recently modified their holdings of the stock. EverSource Wealth Advisors LLC raised its stake in Takeda Pharmaceutical by 38.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company's stock worth $43,000 after buying an additional 859 shares during the period. BNP Paribas Financial Markets raised its position in shares of Takeda Pharmaceutical by 416.0% during the third quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company's stock worth $46,000 after purchasing an additional 2,596 shares during the period. Smithfield Trust Co lifted its holdings in shares of Takeda Pharmaceutical by 76.9% during the 3rd quarter. Smithfield Trust Co now owns 3,428 shares of the company's stock valued at $49,000 after purchasing an additional 1,490 shares in the last quarter. Erste Asset Management GmbH acquired a new position in shares of Takeda Pharmaceutical in the 3rd quarter valued at approximately $52,000. Finally, Headlands Technologies LLC acquired a new position in shares of Takeda Pharmaceutical in the 2nd quarter valued at approximately $59,000. 9.17% of the stock is currently owned by institutional investors and hedge funds.
Takeda Pharmaceutical Stock Down 0.2 %
TAK stock traded down $0.03 during mid-day trading on Friday, hitting $13.42. 1,096,799 shares of the company were exchanged, compared to its average volume of 1,834,104. The firm has a market cap of $42.70 billion, a P/E ratio of 23.14, a P/E/G ratio of 0.26 and a beta of 0.51. Takeda Pharmaceutical Company Limited has a 1-year low of $12.57 and a 1-year high of $15.08. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.77 and a current ratio of 1.28. The firm's 50 day simple moving average is $13.81 and its 200 day simple moving average is $13.87.
About Takeda Pharmaceutical
(
Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Further Reading
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
